Fact Sheet for Health Care Providers: Interpreting Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR) Results

March 17, 2016

Dear Health Care Provider:

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to authorize the use of the Centers for Disease Control and Prevention’s (CDC) Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR) for the in vitro qualitative detection of Zika virus. With specified instruments, this assay tests for Zika virus, dengue virus and chikungunya virus RNA in serum and cerebrospinal fluid (CSF). The assay also tests for Zika virus in urine and amniotic fluid specimens. Testing should only be conducted on specimens from individuals meeting CDC Zika clinical and epidemiological criteria for testing in laboratories designated by the CDC: http://www.cdc.gov/zika/hc-providers/index.html.

FDA issued this EUA based on data submitted by CDC to FDA, and on the U.S. Secretary of Health and Human Services’ (HHS) declaration that circumstances exist to justify the emergency use of in vitro diagnostic tests for the detection of Zika virus and/or diagnosis of Zika virus infection. This EUA will terminate when the HHS Secretary’s declaration terminates, unless FDA revokes it sooner.

The information in this Fact Sheet is to inform you of the significant known and potential risks and benefits of the emergency use of the Trioplex rRT-PCR. For more information on this EUA, please see FDA’s website at (http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm).

Why is this test needed at this time?

As of March 15, 2016, active Zika virus transmission is occurring in 31 countries and territories in the Americas. Among cases identified in 2015-16, Zika virus transmission has occurred primarily through the bite of infected Aedes species mosquitoes. There is increasing evidence that Zika virus can also be transmitted from mother to fetus during pregnancy and through sexual transmission from infected males to their sexual partners.

At this time, there are no FDA approved/cleared tests available that can detect Zika virus in clinical specimens in the United States. Therefore, CDC has developed this test to detect evidence of Zika virus infection, and aid in differentiating this infection from dengue virus infection and chikungunya virus infection. Current information on Zika virus infection for health care providers, including case definitions, is available at http://www.cdc.gov/zika/hc-providers/index.html. All information and guidelines, including those on Zika virus laboratory testing, may change as more data are gathered on this virus. Please check CDC’s Zika virus website regularly for the most current information (http://www.cdc.gov/zika/index.html).

If Zika virus infection is suspected based on current clinical and/or epidemiological criteria recommended by public health authorities, the Trioplex rRT-PCR may be ordered. As dengue virus infection and chikungunya virus infection can have early symptoms resembling those of Zika virus infection, this assay may be useful in differentiating dengue virus infections and
chikungunya virus infections from Zika virus infections or even identifying possible co-infactions. Please contact your state or local health department to facilitate testing. Zika virus RNA is typically detectable in serum for approximately 7 days following onset of symptoms. Persistence of viral RNA in CSF, amniotic fluid and urine is not well characterized but may be longer than in serum.

The results should be used in conjunction with clinical signs and symptoms, epidemiological information and travel history to diagnose Zika virus infection and differentiate Zika virus infections from dengue and chikungunya virus infections. This test is authorized for use with serum and, only when submitted with a patient-matched serum sample, CSF, urine or amniotic fluid.

As of March 15, 2016, serum is the primary diagnostic specimen and should be the priority specimen for collection and testing. Specimens should be collected with appropriate infection control precautions and according to the manufacturer’s instructions for the specimen collection device. Sera should be collected in serum separator tubes and centrifuged after collection to reduce the likelihood of hemolysis.

What are the symptoms of Zika virus infection?

Most people with Zika virus infection exhibit no symptoms. Symptomatic patients typically experience a mild illness characterized by fever, joint pain, rash, or conjunctivitis. The incubation period is unclear, but likely to be several days. Symptoms generally resolve on their own within a week.

Reports from Brazil, a country with a large number of Zika virus cases, indicate an association between Zika virus infection in pregnant women and increased incidence of microcephaly (a birth defect characterized by small head size and impaired cranial and neural development in neonates) as well as central nervous system injury, placental insufficiency, fetal growth restriction, and fetal death. Only limited information is available about the association between Zika virus infection and these adverse outcomes. The likelihood or at what point Zika virus infection may impact fetal development during pregnancy is unknown.

There are also reports from Brazil of a possible association between Zika virus infection and increased incidence of Guillain-Barré syndrome.

As of March 9, 2016, there have been more than 190 confirmed cases of Zika virus infection in the continental United States. All of these individuals have either a recent travel history to areas with ongoing transmission or an epidemiologic link with an individual with such a travel history (i.e., through maternal-fetal or sexual transmission). Public health officials have determined that Zika virus poses a potential public health emergency.

What does it mean if the specimen tests positive for Zika virus RNA?

A positive test for Zika virus from the Trioplex rRT-PCR indicates that RNA from Zika virus was detected in the sera, CSF, urine, or amniotic fluid of the patient. Laboratory test results should always be considered in the context of clinical observations and epidemiologic data in making a final diagnosis and patient management decisions. For guidelines on Zika virus, please refer to http://www.cdc.gov/zika/hc-providers/index.html.
The Trioplex rRT-PCR has been designed to minimize the likelihood of false positive test results. Cross-reactivity of any of the components of this test resulting in false positive results is not expected. However, in the event of a false positive result, risks to patients could include any or all of the following: the impaired ability to detect and receive appropriate medical care for the true infection causing the symptoms, in the case of pregnant women, an unnecessary increase in the monitoring of a woman’s pregnancy, or other unintended adverse effects. Any positive test result for Zika virus should be reported to your local and state health departments.

It should be emphasized that the identification of Zika virus infection in a pregnant woman does not provide any definitive information about the state of health of the fetus. Many questions remain about the association between Zika virus infection in a mother and the impact to the child, and the impact of factors such as timing, likelihood, relevance of symptomatic versus asymptomatic infection. Detection of Zika virus infection in the mother does not mean there is definite harm to the child.

**What does it mean if the specimen tests positive for dengue or chikungunya RNA?**

A positive test for dengue virus or chikungunya virus from the Trioplex rRT-PCR indicates that RNA from dengue and/or chikungunya was detected in specimen. Laboratory test results should always be considered in the context of clinical observations and epidemiologic data in making a final diagnosis and patient management decisions.

The Trioplex rRT-PCR has been designed to minimize the likelihood of false positive test results. Cross-reactivity of any of the components of this test resulting in false positive results is not expected. However, in the event of a false positive result, risks to patients could include any or all of the following: the impaired ability to detect and receive appropriate medical care for the true infection causing the symptoms, or other unintended adverse effects. Any positive test result for dengue or chikungunya virus should be reported to your local and state health departments.

While co-infections are rare, it is possible to detect more than one of these three viruses in patients using this test.

**What does it mean if the specimen tests negative for Zika virus RNA (or dengue virus RNA or chikungunya virus RNA)?**

A negative test for Zika virus, dengue virus and/or chikungunya virus in the specimen means that RNA from Zika virus, dengue virus and/or chikungunya virus is not present in the specimen at the detection level of the assay. However, a negative result for one or more of these arboviruses does not rule out infection with the virus(es) and should not be used as the sole basis for treatment or other patient management decisions.

A negative Trioplex rRT-PCR test result should not be interpreted as demonstrating that the patient has not had Zika virus infection. Negative rRT-PCR tests are known to occur in Zika infection, particularly if testing was conducted more than 7 days after onset of symptoms or in asymptomatic individuals. The possibility of a false negative result should especially be considered if the patient’s recent exposures or clinical presentation indicate Zika virus infection
is likely, and diagnostic tests for other causes of illness are negative. If there is doubt about
the accuracy of the symptom onset date or if the patient lacks symptoms, serological testing of
negative serum specimens may be appropriate to look for evidence of infection.

For CSF, amniotic fluid and urine, it is especially important to note that these are not the
primary diagnostic specimen types. Negative results in these specimen types do not
necessarily mean that an individual is not infected. When negative results are obtained for
these specimens types, attention should be directed to the result for the patient-matched
serum specimen.

If your patient is symptomatic but beyond the window for PCR detection of Zika virus RNA,
serological testing for antibodies to Zika virus may be helpful. In addition, if PCR testing is
negative within seven days of illness onset, serological testing may help to detect infection.
However absence of laboratory evidence of Zika virus infection cannot rule-out Zika virus
infection in persons with epidemiological risk factors. Please refer to CDC guidance for Health
Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible
Zika Virus Exposure:

http://www.cdc.gov/mmwr/volumes/65/wr/mm6505e2er.htm?s_cid=mm6505e2er.htm_w

It is also important to note that Zika virus infection is not the sole suspected cause of
microcephaly in neonates.

Reporting Adverse Events

You should report adverse events, including problems with test performance or results, to
MedWatch at www.fda.gov/medwatch, by submitting a MedWatch Form 3500 (available at
http://www.fda.gov/medwatch/safety/FDA-3500_fillable.pdf) or by calling 1-800-FDA-1088.

Pregnant patients should receive the Fact Sheet for Pregnant Women: Understanding
Results from the Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR).

Give all other patients the Fact Sheet for Patients: Understanding Results from the
Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR).

Contact Information for the Manufacturer:
CDC Emergency Operations Center (EOC)
1600 Clifton Road
Atlanta, Georgia, USA, 30329
Office phone: CDC EOC (770-488-7100)

Any significant new findings observed during the course of the emergency use of the Trioplex
Fact Sheet for Pregnant Women: Understanding Results from the Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR)

March 17, 2016

Dear Madam:

You are being given this Fact Sheet because your blood, urine, cerebrospinal fluid (CSF) or amniotic fluid was tested for evidence of Zika virus infection. This testing is being done because you have symptoms of Zika virus infection and either you live in or have traveled to areas with ongoing Zika virus transmission, or you have a male sex partner who has lived in or traveled to an area with ongoing Zika virus transmission. The test being used on your specimen(s) is called the Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR), which is a laboratory test designed to help detect Zika virus infection in humans. This test can also detect dengue virus and chikungunya virus, which are also transmitted by mosquito bites, and infections with these viruses are seen in many of the same places and share similar symptoms as Zika virus infections.

This Fact Sheet contains information to help you understand the risks and benefits of using the Trioplex rRT-PCR. You may want to discuss with your health care provider the benefits and risks described in this Fact Sheet.

What is Zika virus Infection?
Zika virus infection is caused by the Zika virus and is most often spread to people through mosquito bites. A woman infected with Zika virus during pregnancy can pass the virus to her fetus. Zika virus can be sexually transmitted by a man to his sex partners. Since 2015, a large number of Zika virus cases have been reported in many South and Central American countries.

Most people who are infected with Zika virus do not have any symptoms. Those that do usually have mild illness with symptoms that may include fever, joint pains, rash, or redness of the eyes. These symptoms often resolve on their own within a week.

There have been reports from Brazil of birth defects and other poor pregnancy outcomes in pregnant women with Zika virus infection. The connection between Zika virus infection and pregnancy problems is not well understood. Zika virus infection in a mother does not definitely mean she will have pregnancy problems. A woman who is infected with Zika during pregnancy may have an increased risk of miscarriage, a baby that is stillborn, or a baby that is small at birth, has incomplete brain development, and/or eye problems. Women who get Zika virus while pregnant should be monitored more closely throughout their pregnancy.

There have also been reports of a possible link between Zika virus infection and an illness that can cause temporary paralysis (Guillain-Barré syndrome).

What is the Trioplex rRT-PCR?
The Trioplex rRT-PCR is a laboratory test designed to detect Zika virus and two other viruses, also spread by mosquito bites, which can cause similar symptoms to Zika virus infection: dengue virus and chikungunya virus. The Food and Drug Administration (FDA) has
not cleared or approved this test. No FDA-cleared or approved tests exist that can tell whether you have Zika virus infection or can distinguish or differentiate between Zika virus, dengue virus and chikungunya virus infections. However, FDA has authorized the use of this test under an Emergency Use Authorization (EUA).

**Why is my sample being tested using the Trioplex rRT-PCR?**
You are being tested because you have symptoms that resemble Zika virus infection and because you either live in or have traveled to places with ongoing Zika virus transmission or have had sex with a male sex partner who has lived in or traveled to an area with ongoing Zika virus transmission. The sample(s) collected from you will be tested using the Trioplex rRT-PCR to help find out whether you may be infected with Zika virus or if the cause of your illness is dengue virus or chikungunya virus. The test results, along with other information, could help your doctors make decisions about how to take care of you and better monitor your pregnancy.

**What are the known and potential risks and benefits of the Trioplex rRT-PCR?**
You may feel discomfort when the sample is taken. There is a very small chance that the test result is incorrect (see next paragraphs for more information). The results of this test, along with other information, can help your health care provider make decisions about how to take care of you and your baby.

**If this test is positive for Zika virus, does it mean that I have Zika virus infection?**
If you have a positive test, it is very likely that you have or have had a Zika virus infection. There is a very small chance that this test can give a positive result that is wrong; this is called a false positive result. If your result from this test is positive, your health care provider or health department will work with you to help you understand the steps you should take to care for yourself. They will also work closely with you to monitor the health and development of your child.

**If this test is positive for Zika virus, does it mean that my child will have a birth defect?**
No, not necessarily. The link between Zika virus infection and pregnancy problems such as birth defects, is not well understood. While this test result may lead your doctors to follow your pregnancy more closely, a Zika virus infection in a mother does not always mean the child will be harmed.

**If this test is positive for dengue or chikungunya viruses, does it mean that I have dengue virus infection or chikungunya virus infection?**
If you have a positive test for dengue virus or chikungunya virus, it is very likely you have a dengue virus infection or chikungunya virus infection. There is a very small chance that this test can give a positive result that is wrong (a false positive result). If your result from this test is positive, your health care provider or health department will work with you to help you understand the steps you should take to care for yourself.
If this test is negative for Zika virus (or dengue virus or chikungunya virus), does it mean that I do not have Zika virus infection (or dengue virus infection or chikungunya virus infection)?

A negative test for Trioplex rRT-PCR means that virus was not found in your sample. For Zika virus, a negative result for a sample collected less than a week after the start of illness usually means that Zika virus did not cause your recent illness. Likewise, negative dengue or chikungunya results usually indicate that these viruses did not cause your recent illness.

It is possible for this test to give a negative result that is incorrect (false negative) in some people with a Zika virus infection. Most people with Zika virus infection have virus in their blood for up to a week following the start of illness. A negative result that is incorrect can happen if your body fights a Zika virus infection faster than most other people do. It can also happen if your illness/symptoms started earlier than the date you first noticed them. In these cases, the virus may already be gone from your body before the sample is taken for testing.

If your Zika result for the Trioplex rRT-PCR is negative, you should ask your health care provider or health department if additional testing may be needed. It is important that you work with your health care provider or health department to help you understand the next steps you should take. Your health care provider will work with you to continue to monitor your health and the health of your baby.

What is an Emergency Use Authorization (EUA)?

An EUA is a tool that FDA can use to allow the use of certain medical products for certain emergencies based on scientific data. The U.S. Secretary of Health and Human Services (HHS) has declared that circumstances exist to allow the emergency use of authorized diagnostic tests for Zika virus infection, such as the Trioplex rRT-PCR.

At this time, there are no FDA approved/cleared alternative tests available that detect Zika virus. FDA has authorized the emergency use of the Trioplex rRT-PCR to test for the presence of Zika virus in blood, CSF, amniotic fluid and urine specimens and for differentiation of Zika virus infections from dengue virus and chikungunya virus infections using serum and CSF. Use of this test is authorized only for the duration of the threat of the emergency, unless it is terminated or revoked by FDA sooner.

How can I learn more?

Information about Zika virus and any significant new findings observed during the course of the emergency use of the Trioplex rRT-PCR will be made available at the CDC website: http://www.cdc.gov/zika/index.html.

Please also contact your health care provider if you have any questions.
Fact Sheet for Patients: Understanding Results from the Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR)

March 17, 2016

Dear Patient:

If you are pregnant, please ask your doctor for the Fact Sheet for Pregnant Women: Understanding Results from the Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR).

You are being given this Fact Sheet because your blood, cerebrospinal fluid (CSF) or urine was tested for evidence of Zika virus infection. This testing is being done because you have symptoms of Zika virus infection and you live in or have traveled to an area with ongoing Zika virus transmission. The test being used on your specimen(s) is called the Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR), which is a laboratory test designed to help detect Zika virus infection in humans. This test can also detect dengue virus and chikungunya virus, which are also spread by mosquito bites, and infections with these viruses are seen in many of the same places and share similar symptoms as Zika virus infections.

This Fact Sheet contains information to help you understand the risks and benefits of using the Trioplex rRT-PCR. If possible, you may want to discuss with your health care provider the benefits and risks described in this Fact Sheet.

What is Zika virus Infection?
Zika virus infection is caused by the Zika virus and is most often transmitted to people through mosquito bites. A woman infected with Zika virus during pregnancy can pass the virus to her fetus. Zika virus can also be sexually transmitted by a man to his sex partners. Since 2015, a large number of Zika virus cases have been reported in many South and Central American countries.

Most people who are infected with Zika virus do not have any symptoms. Those that do usually have mild illness with symptoms that may include fever, joint pains, rash, or redness of the eyes. These symptoms often resolve on their own within a week.

There have been reports from Brazil of birth defects and other poor pregnancy outcomes in pregnant women with Zika virus infection. The connection between Zika virus infection and pregnancy problems is not well understood. Zika virus infection in a mother does not definitely mean she will have pregnancy problems, or that she will have an unhealthy baby. A woman who is infected with Zika during pregnancy may have an increased risk of miscarriage, a baby that is stillborn, or a baby that is small at birth, has incomplete brain development, and/or eye problems. Women who get Zika virus infection while pregnant should be monitored more closely throughout their pregnancy. There have also been reports of a possible link between Zika virus infection and an illness that can cause temporary paralysis (Guillain-Barré syndrome).

What is the Trioplex rRT-PCR?
The Trioplex rRT-PCR is a laboratory test designed to detect Zika virus and two other viruses, also spread by mosquito bites, which can cause similar symptoms to Zika virus infection:
dengue virus and chikungunya virus. The Food and Drug Administration (FDA) has not cleared or approved this test. No FDA-cleared or approved tests exist that can tell whether you have Zika virus infection or differentiate between Zika virus infection from dengue chikungunya virus infections. However, FDA has authorized the use of this test under an Emergency Use Authorization (EUA).

Why was my sample tested using the Trioplex rRT-PCR?
You were tested because you have symptoms that resemble Zika virus infection and because you live in or have traveled to an area with Zika virus. The sample(s) collected from you were tested using the Trioplex rRT-PCR to help find out whether you were infected with Zika virus or if the cause of your illness is dengue virus or chikungunya virus. The test results, along with other information, could help your doctors make decisions about how to take care of you and may help limit the spread of Zika virus in your community.

What are the known and potential risks and benefits of the Trioplex rRT-PCR?
You may feel discomfort when the sample is taken. There is a very small chance that the test result is incorrect (see below for more information). The results of this test, along with other information, can help your health care provider make decisions about how to take care of you. Also, knowing your test results may help keep you from giving Zika virus to others.

If this test is positive for Zika virus, does it mean that I have a Zika virus infection?
If you have a positive test, it is very likely that you have or have had a Zika virus infection. There is a very small chance that this test can give a positive result that is wrong; this is called a false positive result. If your result from this test is positive, your health care provider or health department will work with you to help you understand the steps you should take to care for yourself.

If you are male and have a positive test result for Zika virus and you have a pregnant partner or a partner might become pregnant, you should either use a condom the right way every time while your partner is pregnant, or not have sex with your partner to lessen the risk that you may pass Zika virus infection.

If this test is positive for dengue or chikungunya viruses, does it mean that I have dengue virus infection or chikungunya virus infection?
If you have a positive test for dengue virus or chikungunya virus, it is very likely you have a dengue virus infection or chikungunya virus infection. There is a very small chance that this test can give a positive result that is wrong (a false positive result). If your result from this test is positive, your health care provider or health department will work with you to help you understand the steps you should take to care for yourself.

If this test is negative for Zika virus (or dengue virus or chikungunya virus), does it mean that I do not have Zika virus infection (or dengue virus infection or chikungunya virus infection)?
A negative test for Trioplex rRT-PCR means that virus was not found in your sample. For Zika virus, a negative result for a sample collected less than a week after the start of illness usually means that Zika virus did not cause your recent illness. Likewise, negative dengue or chikungunya results usually indicate that these viruses did not cause your recent illness.
It is possible for this test to give a negative result that is incorrect (false negative) in some people with a Zika virus infection. Most people with Zika virus infection have virus in their blood for up to a week following the start of illness. A negative result that is incorrect can happen if your body fights a Zika virus infection faster than most other people do. It can also happen if your illness/symptoms started earlier than the date you first noticed them. In these cases, the virus may already be gone from your body before the sample is taken for testing.

If your Zika result for the Trioplex rRT-PCR is negative, you should ask your health care provider or health department if additional testing may be needed. It is important that you work with your health care provider or health department to help you understand the next steps you should take.

What is an Emergency Use Authorization (EUA)?
An EUA is a tool that FDA can use to allow the use of certain medical products for certain emergencies based on scientific data. The U.S. Secretary of Health and Human Services (HHS) has declared that circumstances exist to allow the emergency use of authorized diagnostic tests for Zika virus infection, such as the Trioplex rRT-PCR.

At this time, there are no FDA approved/cleared alternative tests available that detect Zika virus. FDA has authorized the emergency use of the Trioplex rRT-PCR to test for the presence of Zika virus in blood, CSF, amniotic fluid and urine specimens and for differentiation of Zika virus infections from dengue virus and chikungunya virus infections using serum and CSF. Use of this test is authorized only for the duration of the threat of the emergency, unless it is terminated or revoked by FDA sooner.

How can I learn more?
Information about Zika virus infection and any significant new findings observed during the course of the emergency use of the Trioplex rRT-PCR will be made available at the CDC website: http://www.cdc.gov/zika/index.html.

Please also contact your health care provider if you have any questions.